Article Text

PDF

1123 Do Patent Ductus Arteriosus and its Treatment with Oral Ibuprofen Affect Renal and Mesenteric Tissue Oxygenation in Preterm Infants?
  1. N Guzoglu1,
  2. FN Sari1,
  3. R Ozdemir1,
  4. S Oguz1,
  5. N Uras1,
  6. N Altug2,
  7. U Dilmen1
  1. 1Neonatology
  2. 2Pediatric Cardiology, Zekai Tahir Burak Maternity and Teaching Hospital, Ankara, Turkey

Abstract

Background/Aim Patent ductus arteriosus (PDA) in preterm infants can result in serious hemodynamic changes causing respiratory, gastrointestinal and renal morbidities if not treated within the first week of life. We investigated the impact of PDA and its treatment with oral ibuprofen on regional renal and mesenteric oxygen saturation.

Methods 13 infants with PDA (gestational age < 32 weeks), subsequently treated with oral ibuprofen, were monitored for mean arterial blood pressure, arterial oxygen saturation, near-infrared spectroscopy-determined regional renal and mesenteric oxygen saturation. The patients with PDA were matched for gestational age, birth weight, postnatal age, and severity of respiratory distress syndrome with infants without PDA, who served as control subjects.

Results Median renal and mesenteric oxygen saturation were similar in infants with PDA before and up to 12 hours after the start of ibuprofen therapy [renal oxygen saturation: 50% (25th–75th percentile: 29.5–65.5%) vs. 54% (25th–75th percentile: 36–72.5%), p=0.556; respectively); mesenteric oxygen saturation: 31% (25th–75th percentile: 19–38%) vs. 32% (25th–75th percentile: 23.5–46%), p=0.239; respectively]. Median renal and mesenteric oxygen saturation in control infants were also not significantly different in infants with PDA before and up to 12 hours after the start of ibuprofen therapy.

Conclusions A hemodynamically significant PDA and its adequate treatment with oral ibuprofen seem not to affect the renal and mesenteric perfusion and subsequent oxygen delivery in very low birth weight preterm infants.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.